Assessing Developability of Novel Biotherapeutics Through Mass Spectrometry

Novel biotherapeutics often come with unique structural features and unpredictable behaviors, making early, systematic developability analysis essential. Genedata provides a unified, data‑driven framework that enables teams to evaluate complex molecules with the rigor and throughput modern discovery demands.

Discover how the Genedata biopharma platform integrates biologics formulation software, advanced sequence‑structural analysis software, and comprehensive developability screening software to uncover liabilities across emerging modalities. With built‑in Antibody informatics, support for adc development, and scalable in silico screening software, scientists can rapidly assess stability, manufacturability, and molecular quality—long before costly downstream work begins.

The case study also demonstrates how AI-driven developability prediction software, generative AI protein design software, and next‑generation analytics operationalize AI in drug development, enabling more accurate predictions and faster iteration cycles. As part of a unified developability assessment platform, Genedata empowers organizations to make confident decisions earlier in drug discovery and development, reducing risk while accelerating the advancement of innovative biologics

Genedata Expressionist enables scientists at Sanofi to obtain comprehensive, in-depth characterizations of biotherapeutic candidate molecules. Gaining such a deep molecular understanding of candidates during developability studies leads to much lower attrition rates in later stages, less-problematic processes, and ultimately, a faster time in clinic with best-in-class biotherapeutics.